Patents by Inventor Herbert Y. Meltzer

Herbert Y. Meltzer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11485734
    Abstract: Disclosed are novel small molecules, methods of synthesis of the small molecules, and uses of the small molecules for modulating activity of the human serotonin receptor 2C (5-HT2c), preferably selectively. The small molecules have a substituted beta-carboline core structure, which optionally may be saturated at one or more bonds to provide a dihydro-beta-carboline core or a tetrahydro-beta-carboline core. The small molecules may be administered to treat and/or prevent diseases, disorders, and/or conditions associated with human serotonin receptor 2C (5-HT2C) including psychiatric, mental, and/or neurological diseases, disorders, and conditions such as cognitive impairment, addiction, and obsessive compulsive disorder. The disclosed small molecules also may be administered to treat and/or prevent obesity, for example, via appetite suppression.
    Type: Grant
    Filed: October 2, 2019
    Date of Patent: November 1, 2022
    Assignee: Northwestern University
    Inventors: Karl A. Scheidt, Herbert Y. Meltzer, Adam J. Csakai
  • Publication number: 20220177970
    Abstract: Disclosed are methods, kits, and devices for diagnosing and treating psychiatric disorders and the symptoms thereof. The methods, kits, and devices relate to identifying genetic markers that may be utilized to diagnose and/or prognose a patient and treat the diagnosed and/or prognosed patient by administering a drug the patient based on the genetic marker having been identified. Genetic markers identified in the methods may include HTR2C polymorphisms such as a polymorphism resulting in a Cys23Ser amino acid substitution, an rs3813929 (-759C/T) polymorphism, and an rs518147 (-697G/C) polymorphism).
    Type: Application
    Filed: November 15, 2021
    Publication date: June 9, 2022
    Inventors: Jiang Li, Herbert Y. Meltzer
  • Patent number: 11174514
    Abstract: Disclosed are methods, kits, and devices for diagnosing and treating psychiatric, disorders and the symptoms thereof. The methods, kits, and devices relate to identifying genetic markers that may be utilized to diagnose and/or prognose a patient and treat the diagnosed and/or prognosed patient by administering a drug the patient based on the genetic marker having been identified. Genetic markers identified in the methods may include HTR2C polymorphisms such as a polymorphism resulting in a Cys23Ser amino acid substitution, an rs3813929 (?759C/T) polymorphism, and an rs518147 (?697G/C) polymorphism).
    Type: Grant
    Filed: August 31, 2015
    Date of Patent: November 16, 2021
    Assignee: NORTHWESTERN UNIVERSITY
    Inventors: Jiang Li, Herbert Y. Meltzer
  • Publication number: 20210214352
    Abstract: Disclosed are novel small molecules, methods of synthesis of the small molecules, and uses of the small molecules for modulating activity of the human serotonin receptor 2C (5-HT2c), preferably selectively. The small molecules have a substituted beta-carboline core structure, which optionally may be saturated at one or more bonds to provide a dihydro-beta-carboline core or a tetrahydro-beta-carboline core. The small molecules may be administered to treat and/or prevent diseases, disorders, and/or conditions associated with human serotonin receptor 2C (5-HT2C) including psychiatric, mental, and/or neurological diseases, disorders, and conditions such as cognitive impairment, addiction, and obsessive compulsive disorder. The disclosed small molecules also may be administered to treat and/or prevent obesity, for example, via appetite suppression.
    Type: Application
    Filed: October 2, 2019
    Publication date: July 15, 2021
    Inventors: Karl A. Scheidt, Herbert Y. Meltzer, Adam J. Csakai
  • Publication number: 20200405672
    Abstract: Disclosed are methods for treating a psychiatric disease or disorder and/or symptoms thereof in a subject in need thereof, the method comprising administering to the subject an effective amount of an antagonist of the Na+-K+-2Cl— cation-chloride cotransporter isoform 1 (NKCC1) for treating the psychiatric disorder and/or the symptoms thereof in the subject. The methods further may include administering to the subject a dopamine D1 agonist and/or a GABAA agonist, optionally at a subeffective dose, where co-administering the antagonist of NKCC1 improves the efficacy of the dopamine D1 agonist and/or the GABAA agonist, optionally at the subeffective dose, for treating the psychiatric disease or disorder and/or symptoms thereof.
    Type: Application
    Filed: June 29, 2020
    Publication date: December 31, 2020
    Applicant: NORTHWESTERN UNIVERSITY
    Inventors: Marco Martina, Herbert Y. Meltzer
  • Patent number: 10654865
    Abstract: Enantioselective syntheses of cis- and trans-bicyclic dihydropyran compounds, and other intermediates, en route to heteroyohimbine alkaloids.
    Type: Grant
    Filed: June 12, 2019
    Date of Patent: May 19, 2020
    Assignee: NORTHWESTERN UNIVERSITY
    Inventors: Karl A. Scheidt, Ashkaan Younai, Bi-Shun Zeng, Herbert Y. Meltzer
  • Publication number: 20190300540
    Abstract: Enantioselective syntheses of cis- and trans-bicyclic dihydropyran compounds, and other intermediates, en route to heteroyohimbine alkaloids.
    Type: Application
    Filed: June 12, 2019
    Publication date: October 3, 2019
    Inventors: Karl A. Scheidt, Ashkaan Younai, Bi-Shun Zeng, Herbert Y. Meltzer
  • Publication number: 20190264285
    Abstract: Disclosed are methods, kits, and devices for diagnosing and treating psychiatric disorders and the symptoms thereof. The methods, kits, and devices relate to identifying genetic markers that may be utilized to diagnose and/or prognose a subject and treat the diagnosed and/or prognosed subject by administering a drug the subject based on the genetic marker having been identified. Genetic markers identified in the methods may include a polymorphism in a gene encoding a protein associated with synaptogenic adhesion, scaffolding, neuron-specific splicing regulation, potassium channels which form leak conductances that regulate neuronal excitability, synaptic spine turnover and stability of synaptic contacts, and/or vesicle trafficking and exocytosis in presynaptic neurons and neuromuscular junctions.
    Type: Application
    Filed: February 25, 2019
    Publication date: August 29, 2019
    Applicant: Northwestern University
    Inventors: Jiang Li, Herbert Y. Meltzer
  • Patent number: 10323039
    Abstract: Enantioselective syntheses of cis- and trans-bicyclic dihydropyran compounds, and other intermediates, en route to heteroyohimbine alkaloids.
    Type: Grant
    Filed: May 3, 2016
    Date of Patent: June 18, 2019
    Assignee: Northwestern University
    Inventors: Karl A. Scheidt, Ashkaan Younai, Bi-Shun Zeng, Herbert Y. Meltzer
  • Patent number: 10098893
    Abstract: Disclosed are methods and kits for diagnosing, prognosing, and treating patients having psychiatric disorders. The methods may include assessing whether a patient has a treatment resistant psychiatric disorder or assessing whether the patient is likely to develop a treatment resistant psychiatric disorder. The methods may include detecting genetic markers such as the single nucleotide polymorphism (SNP) in genes present in a genomic nucleic acid sample from the patient, and/or receiving, as a caregiver, the results of tests indicating whether the genetic markers are present in the genomic nucleic acid sample from the patient. The methods may include administering treatment to the patient, for example, based on the detected genetic markers, and administering treatment may include administering new antipsychotic drugs (APDs) that are trace amine-associated receptor 1 (TAAR1) agonists.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: October 16, 2018
    Assignee: Northwestern University
    Inventors: Jiang Li, Herbert Y. Meltzer
  • Publication number: 20160326183
    Abstract: Enantioselective syntheses of cis- and trans-bicyclic dihydropyran compounds, and other intermediates, en route to heteroyohimbine alkaloids.
    Type: Application
    Filed: May 3, 2016
    Publication date: November 10, 2016
    Inventors: Karl A. Scheidt, Ashkaan Younai, Bi-Shun Zeng, Herbert Y. Meltzer
  • Publication number: 20160060702
    Abstract: Disclosed are methods, kits, and devices for diagnosing and treating psychiatric, disorders and the symptoms thereof. The methods, kits, and devices relate to identifying genetic markers that may be utilized to diagnose and/or prognose a patient and treat the diagnosed and/or prognosed patient by administering a drug the patient based on the genetic marker having been identified. Genetic markers identified in the methods may include HTR2C polymorphisms such as a polymorphism resulting in a Cys23Ser amino acid substitution, an rs3813929 (?759C/T) polymorphism, and an rs518147 (?697G/C) polymorphism).
    Type: Application
    Filed: August 31, 2015
    Publication date: March 3, 2016
    Applicant: NORTHWESTERN UNIVERSITY
    Inventors: Jiang Li, Herbert Y. Meltzer
  • Publication number: 20150099741
    Abstract: Disclosed are methods and kits for diagnosing, prognosing, and treating patients having psychiatric disorders. The methods may include assessing whether a patient has a treatment resistant psychiatric disorder or assessing whether the patient is likely to develop a treatment resistant psychiatric disorder. The methods may include detecting genetic markers such as the single nucleotide polymorphism (SNP) in genes present in a genomic nucleic acid sample from the patient, and/or receiving, as a caregiver, the results of tests indicating whether the genetic markers are present in the genomic nucleic acid sample from the patient. The methods may include administering treatment to the patient, for example, based on the detected genetic markers, and administering treatment may include administering new antipsychotic drugs (APDs) that are trace amine-associated receptor 1 (TAAR1) agonists.
    Type: Application
    Filed: October 3, 2014
    Publication date: April 9, 2015
    Applicant: Northwestern University
    Inventors: Jiang Li, Herbert Y. Meltzer
  • Patent number: 8735397
    Abstract: The invention relates to a method for treating schizophrenia and/or related diseases comprising administering lurasidone and a mGluR2 ligand to a mammal in need thereof.
    Type: Grant
    Filed: March 28, 2011
    Date of Patent: May 27, 2014
    Assignees: Vanderbilt University, Dainippon Sumitomo Pharma Co., Ltd.
    Inventors: Herbert Y. Meltzer, Masakuni Horiguchi
  • Publication number: 20110237602
    Abstract: The invention relates to a method for treating schizophrenia and/or related diseases comprising administering lurasidone and a mGluR2 ligand to a mammal in need thereof.
    Type: Application
    Filed: March 28, 2011
    Publication date: September 29, 2011
    Applicants: Vanderbilt University, Dainippon Sumitomo Pharma Co., Ltd.
    Inventors: Herbert Y. MELTZER, Masakuni Horiguchi
  • Patent number: 5221679
    Abstract: The invention relates to a method of treating therapy-resistant schizophrenia which includes administering a therapeutically effective amount of melperone (4-fluro-.gamma.-(4-methyl-piperidino)-butyrophenone) or an acceptable acid salt thereof.
    Type: Grant
    Filed: March 16, 1992
    Date of Patent: June 22, 1993
    Assignee: Case Western Reserve University
    Inventor: Herbert Y. Meltzer